Commure Startup Diligence Report
Commure looks strategically differentiated if its public claims about 130+ health systems, 40M ambient appointments, 85%+ RCM automation and clinician-led product development hold up under private diligence; however, the same breadth creates integration risk, and the Canopy / Strongline dispute is a material legal and product-line caution flag.
Commure Startup Diligence Report
Commure’s public record supports a strong thesis that it has grown into a broad healthcare AI infrastructure company with meaningful enterprise traction, but public diligence stops well short of validating financial quality, customer concentration, legal downside and governance economics.
The Canopy dispute already produced an injunction affecting Strongline Pro activity and publicly exposed uncertainty over technology rights and customer-support control in a staff-safety product line.
Diligence request: Have counsel review every Strongline agreement, court filing, customer notice and any settlement / transition documentation before underwriting the business line.
Commure’s public record contains compelling headline growth and valuation signals, but not audited statements, cohort retention, margin detail, cash burn or the detailed terms needed to underwrite a private-company valuation.
Diligence request: Request audited financials, KPI pack, board valuation support, cash/debt schedule and customer-cohort detail before relying on public scale metrics.
Commure is competing simultaneously with ambient AI specialists like Abridge and Suki, AI-RCM vendors like AKASA, and incumbents like R1, which can pressure win rates and pricing.
Diligence request: Run win/loss analysis, product bake-offs and independent customer references by product line and buyer type.
Commure’s public product span is unusually broad and the company said it completed four acquisitions while scaling rapidly, increasing the odds of uneven product quality, roadmap slippage or integration debt.
Diligence request: Request architecture review, incident/change management data, roadmap dependencies, product-line P&Ls and post-acquisition integration scorecards.
Commure’s public traction centers on large provider systems and multi-stakeholder pilots, which can produce concentrated ARR, heavy implementation cost and elongated conversion / renewal cycles.
Diligence request: Request top-account ARR concentration, pilot-to-rollout conversion, implementation margin, renewal performance and source-of-pipeline data.
Commure’s privacy, security and HIPAA posture is visible publicly, but the strongest evidence available is still mostly vendor-controlled copy and a public template BAA rather than third-party reports or regulator correspondence.
Diligence request: Obtain SOC 2 report, pen-test reports, HIPAA risk assessments, incident history, cyber-insurance schedule and counsel review of any regulator matters.
General Catalyst appears repeatedly as investor, financier and strategic backer, while the CVF structure uses a non-standard repayment mechanism tied to customer cohorts.
Diligence request: Request the signed financing documents, board rights, payback mechanics, covenants and any preferred-security waterfall analysis.
A company claiming 3,000+ global employees after four acquisitions with only sparse public headcount, attrition and hiring-plan visibility deserves extra retention and org-design scrutiny.
Diligence request: Request HRIS extracts, attrition data, engagement surveys, compensation plans, refresh-grant schedules and integration plans by acquired entity.
Public sources confirm major 2025-26 financing events and some scale metrics, but not investment-grade financial quality, ownership detail or projection support.
not publicly verifiable confidence: low
Public evidence provides headline ARR, run-rate and claims-volume signals, but not audited statements, AR aging, backlog or product/geography gross-profit schedules.
| metric | public value | source context | verification status | diligence note |
|---|---|---|---|---|
| Annual recurring revenue | Hundreds of millions; doubled for three consecutive years | June 2025 $200M CVF financing release | partially_verified | No audited revenue bridge, churn, NRR or cohort disclosure was public. |
| Combined run rate | $100M+ run rate; tracking to $125M-$150M by year-end | March 2026 Athelas merger announcement | partially_verified | The run-rate basis, contribution by legacy business and margin quality are not public. |
| Platform scale | 130+ health systems; 500+ healthcare organizations; 3,000+ sites of care | 2025-26 financing and customer press materials | partially_verified | Counts are marketing-style and use slightly different denominators across pages. |
| RCM throughput and automation | $25B+ annual claims / tens of billions in annual payments; 85%+ of work without human intervention | 2026 financing and related company materials | partially_verified | Automation-rate definition, exception handling and claim-denial economics are not public. |
| Gross margin, burn, debt, cash, NRR, CAC payback, AR aging | Not publicly disclosed | Public-source review across company, database and customer materials | not_publicly_verifiable | Requires audited financials, board package, KPI pack and lender documents. |
Public metrics are directionally positive but too high-level to underwrite the valuation.
partially verified confidence: medium
Growth drivers and a run-rate target are public, but no full forecast model, scenario set or capital plan was accessible.
Mixed-source chart; treat as high-level anchor only.
not publicly verifiable confidence: low
Public sources identify selected investors and a merged operating structure, but not the actual cap table, debt schedule or option overhang.
| stakeholder or security | public position | evidence | diligence caveat |
|---|---|---|---|
| General Catalyst | Select investor on CB Insights; lead on $200M CVF financing and $70M 2026 round; provider of fresh merger capital | Appears repeatedly across 2025 and 2026 financing materials and in the CB Insights row. | Exact ownership, board rights and CVF economics are not public. |
| HCA Healthcare | Select investor on CB Insights and marquee strategic customer / co-development partner | Listed in CB Insights row and highlighted in the 2024 ambient AI deployment announcement. | Stake size and any strategic rights are not public. |
| Sequoia Capital; Morgan Stanley; Kirkland & Ellis | Participants in the 2026 financing round | Named in the May 2026 financing release. | No public ownership percentages or instrument terms. |
| Athelas / combined operating structure | Merged operating combination with Tanay as CEO, Deepika as COO and Dhruv as CTO | Athelas merger page describes combined-company leadership and valuation. | The exact legal structure, share exchange ratio and subsidiary boundaries are not public. |
| Employee options, debt, warrants and off-balance-sheet liabilities | Not publicly disclosed | Accessible public sources disclosed financing headlines but no detailed cap-table or debt schedule. | Requires cap table, option register, debt documents and board materials. |
This table is intentionally conservative and should be reconciled against signed financing documents and the current capitalization table.
partially verified confidence: medium
Commure’s financing history is the richest public financial topic; tax positions, accounting policies and detailed financing mechanics remain private.
| date | event | amount usd m | valuation usd b | investors or counterparties | public evidence | verification status |
|---|---|---|---|---|---|---|
| 2026-03 (current list) | CB Insights unicorn-list valuation anchor | — | 6 | General Catalyst; HCA Healthcare listed as select investors | CB Insights current unicorn list row shows Commure at $6B in Mountain View. | verified |
| 2025-06-19 | General Catalyst CVF growth financing | 200 | — | General Catalyst Customer Value Fund | Company said CVF financing would fund surging demand and be repaid from a capped share of acquired-customer cohorts. | verified |
| 2026-03-05 | Athelas + Commure merger announcement and fresh capital | — | 6 | General Catalyst fresh capital | Merger page said the combined entity was being valued at $6B. | partially_verified |
| 2026-05-19 | New financing round | 70 | 7 | General Catalyst (lead), Sequoia Capital, Morgan Stanley, Kirkland & Ellis | Company press release disclosed the round and investor set. | verified |
Public sources were enough to build a valuation trajectory, but not to validate dilution, liquidation preferences or debt covenants.
Commure publicly presents a broad multi-product healthcare-AI platform spanning clinical documentation, revenue cycle, patient engagement, agentic workflows, staff safety and diagnostics.
partially verified confidence: medium
Product pages provide unusually rich public positioning detail, but most performance metrics still originate from Commure-controlled sources.
| product | audience | public positioning | key features or metrics | verification status |
|---|---|---|---|---|
| Ambient AI | Clinicians and enterprise health systems | Clinical documentation platform that listens, codes, cues and connects. | 40M appointments annually; 60+ EHR integrations; multiple tiers including Ambient AI / Assist / Live / +. | partially_verified |
| RCM | Revenue-cycle leaders, practices and health systems | End-to-end automation for coding, prior auth, eligibility, submissions, posting and appeals. | Denial Copilot, same-day claim submissions, patient payments, EHR-embedded workflows. | verified |
| Dictation | Clinicians documenting inside any text field or EHR surface | AI voice platform for clinical documentation and speech-to-cursor control. | Built on the same AI powering tens of millions of ambient encounters; downstream content generation. | verified |
| Agents | Patient-access, billing and prior-auth teams | AI-powered colleagues for healthcare operations. | AI Call Center, Scheduling, Billing, Patient Outreach, Prior Authorization and Denials Autopilot agents. | verified |
| Engage | Access, outreach and care-coordination teams | AI-powered patient engagement across intake, call center and ongoing care. | Automated SMS follow-ups, referral management, care pathways and conversational AI. | verified |
| Commure Pro | Clinical and revenue-integrity teams | Clinical intelligence platform for modern care delivery. | Combines AI-driven documentation, autonomous coding, charge-note reconciliation and revenue integrity. | verified |
| Strongline | Hospital staff-safety and RTLS teams | Wearable staff safety and asset-tracking platform. | Duress badges, proximity alerts, RTLS, 50K+ alerts since 2024, 24/7/365 support. | partially_verified |
| Athelas Home | Care teams managing point-of-care or at-home blood monitoring | Rapid blood diagnostics at the point of care and at home. | FDA-cleared, CLIA-waived hematology analyzer for WBC count and neutrophil percentage. | partially_verified |
The product matrix shows unusual platform breadth for a private healthcare AI company, which is strategically powerful but executionally demanding.
| product or peer | public pricing visibility | observed packaging signal | source page | diligence note |
|---|---|---|---|---|
| Ambient AI | No public pricing located | Tiered packaging (Ambient AI / Assist / Live / +) implies differentiated commercial offers. | Ambient AI product page | Need list price, ASP, specialty pricing and discount policy. |
| RCM | No public pricing located | Full-stack RCM workflow scope suggests custom enterprise packaging. | RCM product page | Need fee model, implementation charges, performance components and service mix. |
| Dictation | No public pricing located | Page claims enterprise-grade voice is “priced to make” deployment accessible but no rates are shown. | Dictation product page | Need seat pricing, bundle logic with Ambient and win/loss pricing benchmarks. |
| Engage / Agents / Commure Pro | No public pricing located | Demo-led enterprise software motion with workflow bundles and no self-serve checkout. | Homepage and product pages | Need module-level pricing, implementation scope and pricing power by buyer segment. |
No accessible public competitor pricing was sufficiently robust to build a fair apples-to-apples comparison, so the table focuses on the visibility gap itself.
Public customer stories support real traction and measurable workflow outcomes, but customer concentration, contract value and supplier economics remain largely private.
partially verified confidence: medium
Commure publicly names multiple marquee customers and publishes several quantified case studies across ambient AI, Engage and RCM.
| customer | product area | public outcome | source | verification status |
|---|---|---|---|---|
| HCA Healthcare | Ambient AI | Selected Commure as exclusive ambient AI partner; formal enterprise agreement was still being negotiated at announcement. | 2024 HCA press release | partially_verified |
| Tenet Healthcare | Ambient AI | Enterprise-wide deployment across employed physician network; page cites 81% reduction in overall clinical documentation time. | Tenet customer landing page | partially_verified |
| Willis Knighton Health | Ambient AI | Won competitive seven-specialty pilot; 88% of providers reported benefits and 95% would recommend. | Willis Knighton press release | partially_verified |
| North East Medical Services (NEMS) | Ambient AI / Epic integration | 30% daily documentation-efficiency improvement; 95% Spanish and 93% Chinese transcript accuracy in pilot. | NEMS customer story | partially_verified |
| Unnamed NYC health system | RCM / Commure Pro | Charges increased from $7.5M to $9.4M; collections from $2.2M to $2.8M; timely-filing denials fell from 68% to 32%. | NYC RCM customer story | partially_verified |
| Yale New Haven Health | Engage | 54% relative reduction in no-shows and same-day cancellations; 19,103 reminders sent. | Yale New Haven customer story | partially_verified |
| A&A Women’s Health / Dignity Health physician examples | Ambient AI | Customer page highlights 23% average charting-time reduction and 41% charting-time reduction examples. | Commure customers page | partially_verified |
These references support traction and product fit, but not customer concentration, durability or contract economics.
partially verified confidence: medium
Strategic relationships are most visible through EHR channels, marquee health-system partnerships and the Canopy operating transition.
| partner | relationship type | public evidence | strategic value | gap or caveat |
|---|---|---|---|---|
| Epic | Marketplace / EHR channel | Commure Ambient AI is officially part of Epic Toolbox. | Improves discoverability and trust inside Epic-heavy provider networks. | Pipeline sourced from Epic is not public. |
| Cerner / Oracle Health | Workflow integration | Ambient notes sync into DynDoc or PowerNote and sign in PowerChart. | Strengthens penetration into legacy Oracle/Cerner estates. | Commercial terms and support obligations are not public. |
| MEDITECH | EHR compatibility / channel enhancer | Willis Knighton cited MEDITECH Expanse compatibility in selecting Commure. | Supports penetration into MEDITECH-powered community and regional systems. | No public reseller economics or certification level beyond public references. |
| AWS | Agentic AI thought-leadership and infrastructure alignment | Commure hosted a public webinar with AWS healthcare AI leadership. | Signals cloud/AI ecosystem credibility and enterprise infrastructure dependence. | The exact production cloud footprint and spend concentration are not public. |
| Canopy | Post-dispute operating partnership | Canopy said it would assume management and support of Commure Strongline customers going forward. | Reduces near-term customer-disruption risk in staff safety but underscores legal and control complexity. | Long-term economics and IP-resolution terms are not public. |
Strategic relationships are clearly important to Commure’s distribution model, but revenue contribution and exclusivity terms remain largely private.
not publicly verifiable confidence: low
No accessible public source disclosed revenue concentration by customer or whether any single account exceeds 5% of revenue.
partially verified confidence: medium
The Canopy / Strongline dispute and later support partnership are the clearest public relationship-change signals in the accessible record.
partially verified confidence: medium
Public sources mainly reveal technology and channel dependencies rather than spend-ranked suppliers.
| supplier or dependency | role | public evidence | concentration risk note | verification status |
|---|---|---|---|---|
| EHR ecosystem (60+ systems) | Core data-ingestion and workflow-embedding layer | Commure says it integrates with 60+ EHRs and markets deep EHR-embedded workflows. | Certification delays, API policy shifts or integration breakage could impair deployments. | partially_verified |
| Epic / Epic Toolbox | Channel access and mobile/documentation distribution | Epic Toolbox listing and Epic customer references are public. | Epic roadmap or marketplace-policy changes could affect GTM leverage. | partially_verified |
| Cerner / Oracle Health | Clinical workflow embedding inside PowerChart, DynDoc and PowerNote | Commure’s Cerner integration blog describes direct note sync and sign-off inside Oracle workflows. | Workflow depth creates switching costs but also support and roadmap dependency. | partially_verified |
| AWS | AI and infrastructure ecosystem partner | Commure publicly co-hosted agentic-AI content with AWS healthcare AI leadership. | Cloud cost, model-availability or compliance changes could affect roadmap speed. | partially_verified |
| Anthropic / model providers | Frontier-model layer for healthcare-grade AI workflows | Commure says it has deployed Anthropic “Mythos-class” models inside its environment. | Model-vendor pricing, policy or performance shifts could change unit economics and product behavior. | partially_verified |
| Canopy licensed technology for Strongline | Historical staff-safety technology rights and support dependency | Court order says Canopy retained IP rights in licensed technology; later partnership put Canopy in customer-support role. | A dispute over a key dependency can directly constrain product sales and servicing. | verified |
The main public supplier/dependency insight is that Commure’s product depth likely requires strong vendor-management discipline across EHR, cloud and model providers.
Commure competes across several categories at once: ambient AI specialists, AI-native revenue-cycle vendors, and scaled incumbent RCM platforms.
partially verified confidence: medium
Public sources suggest Commure differentiates on breadth, but it faces specialists that may outperform on focus and incumbents that outperform on maturity.
| competitor | segment | public scale signal | product overlap | differentiator or gap | source |
|---|---|---|---|---|---|
| Commure | Ambient AI + AI-native enterprise RCM + provider infrastructure | 130+ health systems / 150+ enterprise health systems; 2,000+ sites of care; 3,000+ workforce claim | Reference row | Broadest public workflow span in this set, but with higher execution complexity. | Commure-owned sources |
| Abridge | Ambient documentation / clinical-conversation intelligence | Trusted by 300+ health systems | Competes in ambient capture, documentation and downstream clinical actions. | Appears deeper in pure ambient focus; less publicly broad than Commure on RCM and staff-safety adjacency. | Abridge homepage |
| Suki | Ambient clinical intelligence | Deep integrations with Epic, Oracle Health, athenahealth and MEDITECH | Competes in ambient documentation and clinician workflow AI. | Appears more task-specific than Commure’s broader RCM/Engage/Strongline mix. | Suki homepage |
| AKASA | Generative AI for healthcare revenue cycle | Client base represents 650+ hospitals and 6,500+ outpatient facilities | Competes in AI-enabled revenue-cycle automation. | More RCM-focused; lacks Commure’s public ambient / safety / patient-engagement breadth. | AKASA homepage |
| R1 | Scaled incumbent RCM platform | 280m transactions each year; system-level automation claims | Competes in revenue-cycle automation and enterprise-provider commercial motion. | R1 is the mature incumbent benchmark; Commure differentiates with AI-native and ambient/clinical adjacency. | R1 homepage |
Funding totals for competitors were not consistently accessible in public sources during this run, so the table focuses on positioning and footprint rather than private financing comps.
| axis | commure position | top competitors position | evidence |
|---|---|---|---|
| Workflow breadth | High | Abridge/Suki lower; AKASA and R1 narrower around RCM | Commure publicly spans ambient AI, RCM, agents, engagement, staff safety and home diagnostics. |
| Ambient documentation depth | High but contested | Abridge and Suki are strong specialists | Commure public pages show ambient tiers and large-scale deployment claims, but Abridge and Suki are pure-play ambient competitors. |
| RCM automation breadth | High | AKASA and R1 are strong focused comparators | Commure’s RCM product scope and public customer outcomes overlap with AKASA’s AI-RCM and R1’s scaled OS framing. |
| EHR ecosystem coverage | High | Suki emphasizes the four leading EHRs; others less visibly broad | Commure publicly claims 60+ EHRs plus Epic Toolbox and Oracle/Cerner-specific embedding. |
| Execution and legal complexity | Elevated risk | Specialists may have narrower scope, though their own legal exposure is outside this run | Commure’s breadth, acquisition pace and Strongline litigation increase execution complexity. |
This table is deliberately qualitative: public sources are good enough to compare strategic shape, not to calculate exact share, pricing or gross-margin advantage.
Public GTM signals point to direct enterprise sales amplified by EHR channels, customer-story marketing and partner/co-sell programs.
partially verified confidence: medium
Commure’s public GTM posture is centered on health-system digital transformation, workflow ROI and distribution through incumbent clinical systems.
| channel | public evidence | region or segment | proof point | gap |
|---|---|---|---|---|
| Direct enterprise health-system sales | Customers page, HCA, Tenet and Willis references | Large U.S. provider systems | Commure publicly references 130+ / 150+ health systems and several marquee deployments. | Pipeline, ACV, sales cycle and concentration are not public. |
| Pilot-to-enterprise conversion | NEMS and Willis stories explicitly describe pilots and evaluation processes | Health systems evaluating ambient AI | Willis cited a seven-specialty pilot; NEMS compared multiple AI scribing tools. | Conversion rates across the broader funnel are not public. |
| EHR ecosystem distribution | Epic Toolbox, Cerner integration, 60+ EHR partner page | Epic, Oracle/Cerner, MEDITECH and other EHR users | Marketplace placement and deep EHR workflow embedding lower adoption friction. | Revenue attribution by EHR channel is not public. |
| Co-sell / partner / GPO motion | Partners page describes system integrators and GPOs as opening channels and co-selling bundled solutions. | Digital-transformation leaders at health systems | Public language suggests Commure is leaning on partner access to executive buyers. | Named partner roster and sourced-pipeline share are not public. |
| AI ecosystem thought leadership | AWS webinar and Anthropic deployment blogs | Innovation-minded provider executives | Public content supports category education and technical credibility. | The direct lead-generation impact of content marketing is not public. |
Commure’s public GTM posture looks enterprise-heavy and partner-amplified rather than self-serve.
partially verified confidence: medium
Major-customer names and a few outcome case studies are public, but relationship quality and future expansion economics are not.
partially verified confidence: medium
New-business generation appears to run through EHR ecosystems, partner programs, customer references and competitive pilots.
| signal type | public example | date or scope | implication | source |
|---|---|---|---|---|
| Owned educational content library | Homepage resources split by clinicians, executives and finance with blogs, customer stories, webinars, reports and guides. | Current homepage structure | Suggests segmented messaging by buyer persona. | Homepage |
| Marquee deployment announcements | HCA, Willis Knighton and financing press releases | 2024-2026 | Commure uses major logos and capital raises as credibility builders. | Press releases |
| EHR marketplace and integration announcements | Epic Toolbox and Cerner workflow-embedding blogs | 2025-04 to 2026-05 | Distribution narrative emphasizes “built where clinicians already work.” | Company blogs |
| AI ecosystem thought leadership | AWS healthcare webinar and Anthropic model-deployment blog | Current 2026 content set | Supports positioning as an AI infrastructure platform, not just a workflow app. | Company blogs |
| Case-study storytelling | Customer page highlights documentation, no-show and revenue-cycle outcomes across named health systems. | Current customers page | The GTM narrative leans heavily on measured workflow ROI. | Customers page |
These are signal counts and messaging anchors, not a substitute for attributable pipeline data.
not publicly verifiable confidence: low
Public sources describe how Commure goes to market, not how the sales force is compensated or measured.
not publicly verifiable confidence: low
Budget sufficiency was not publicly observable in the accessible sources.
Public R&D signals show clinician-led design, forward-deployed engineering and active product launches, but not the cost structure or development velocity behind them.
partially verified confidence: medium
Commure publicly highlights its Clinical Council, forward-deployed engineering model and named clinician-product leaders.
| name | role | public background | source | verification status |
|---|---|---|---|---|
| Deepika Bodapati | COO and co-founder | Named COO in merger and female-founders recognition materials; central operator in combined company. | Merger / company press | verified |
| Jamie Colbert, MD | Chief Medical Officer | Clinical Council page says she previously served as CMO at Memora Health and maintains clinical practice at Mass General Brigham. | Clinical Council | verified |
| Aabha Morey | Clinical AI Strategy lead | Leads clinical AI strategy for autonomous coding and CDS across enterprise customers. | Clinical Council and Patient 360 blog | verified |
| Jean-Luc Neptune, MD, MBA | Clinical Commercial Leader | Physician executive focused on growth and profitability of AI-powered products. | Clinical Council | verified |
| Donald Lazure, PA, MA, MMSc | Clinical Strategy Lead | Brings surgery, critical-care, AI documentation and Microsoft/Nuance experience. | Clinical Council | verified |
| Dhruv (surname not stated in source excerpt) | CTO | Named CTO of the combined Athelas + Commure entity in the merger announcement. | Athelas merger page | partially_verified |
The public R&D roster skews clinician-heavy, which is strategically valuable but still not a full org design or headcount map.
partially verified confidence: medium
Recent public materials show active feature rollout and continued investment in the shared intelligence layer, but not a detailed roadmap or costed schedule.
| initiative | status | public timing signal | source | verification status |
|---|---|---|---|---|
| Patient 360 / Pre-Visit Summary | Released to over a thousand providers across multiple specialties | June 2026 blog post | Patient 360 blog | partially_verified |
| Shared intelligence layer beneath every workflow | Active investment priority | May 2026 financing release | 2026 financing release | partially_verified |
| Agentic systems handling payer rules, specialty coding, denial patterns and clinical context | Public roadmap priority | May 2026 financing release | 2026 financing release | partially_verified |
| Global healthcare market expansion | Public expansion objective | May 2026 financing release | 2026 financing release | partially_verified |
Public roadmap evidence is encouraging but does not expose R&D spend, release quality or delivery confidence by module.
Public management signals are credible but incomplete, and the workforce story is dominated by one very large self-reported headcount anchor plus a handful of hiring anecdotes.
partially verified confidence: medium
A partial organization chart can be assembled from public titles, but it is not a substitute for the real reporting structure.
partially verified confidence: medium
The public record contains one meaningful total-workforce anchor, some recruiting-team signals and a current zero-openings snapshot, but no credible full trendline.
| signal | value | date or context | source | verification status |
|---|---|---|---|---|
| Total workforce | Over 3,000 employees globally | June 2025 people-team blog after four acquisitions | Jason Scales profile | partially_verified |
| Recruiting-team size | From 2 to close to 10 | August 2025 recruiting blog | Ashley talent profile | partially_verified |
| Hiring breadth | Sales, Product, Marketing, Engineering, Accounting, Finance and Operations | Ashley recruiting blog | Ashley talent profile | verified |
| Current open positions at crawl time | 0 open positions | Careers page accessed 2026-06-14 | Careers page | inconclusive |
| Public location anchor | Mountain View, CA 94043, United States | Careers page accessed 2026-06-14 | Careers page | verified |
The public staffing picture is sparse and should be treated as directional only.
partially verified confidence: medium
Several senior leaders have enough public biography detail to support screen-level diligence, especially on the clinical side.
| name | role | public anchor | prior background | source |
|---|---|---|---|---|
| Tanay Tandon | CEO | 2026 financing release and merger page | Publicly positioned as leader of the combined company and primary financing spokesperson. | Financing / merger materials |
| Deepika Bodapati | COO; co-founder | Merger page and 2026 recognition press release | Public operator and co-founder of Commure. | Merger / company press |
| Dhruv (surname not stated in source excerpt) | CTO | Merger page | Named technology leader of the combined entity. | Merger page |
| Jamie Colbert, MD | Chief Medical Officer | Clinical Council page | Former Memora Health CMO; active clinical practice and Harvard Medical School adjunct professor. | Clinical Council |
| Ian Shakil | Chief Strategy Officer | Willis Knighton press release quote attribution | Quoted as CSO in public ambient-AI partnership release. | Willis Knighton release |
| Daniel Brian | Privacy officer; likely senior legal lead | Privacy policy | Named contact for privacy matters; no full public bio was visible in accessible sources. | Privacy policy |
This is a public-facing roster, not a full management hierarchy or governance chart.
not publicly verifiable confidence: low
Compensation and employment terms were not publicly disclosed in the accessible source set.
not publicly verifiable confidence: low
No public incentive-plan detail was available beyond the general fact that Commure is a private growth company.
inconclusive confidence: low
No significant employee-relations issue was verified in accessible public sources, but the evidence set is too limited to clear the topic.
inconclusive confidence: low
Turnover data is not public; only indirect signals from recruiting growth, acquisitions and open-role snapshots are available.
| signal | public evidence | interpretation | source | verification status |
|---|---|---|---|---|
| Acquisition-integration load | People leader said Commure completed four acquisitions in roughly a year. | Integration load can raise turnover and org-design risk even if it supports scale. | Jason Scales profile | partially_verified |
| Rapid recruiting-team buildout | Recruiting team expanded from 2 to close to 10 and hired across nearly every major function. | Suggests prior hypergrowth, which often precedes retention and onboarding strain. | Ashley talent profile | partially_verified |
| Current public turnover disclosure | No direct public attrition schedule or verified layoff disclosure surfaced in accessible sources; careers page showed 0 open roles at crawl time. | The absence of reliable turnover data is itself a diligence gap. | Public-source review / careers page | inconclusive |
This table is intentionally conservative: public sources are not enough to quantify attrition or retention-plan effectiveness.
The public legal record is dominated by the Canopy / Strongline dispute, while privacy, security and template HIPAA commitments are visible but only partly independently verifiable.
verified confidence: high
A public federal injunction in the Canopy matter is the most material known legal issue against Commure in the accessible sources.
| case | court or source | filed or decision date | status | public summary |
|---|---|---|---|---|
| Canopy / Strongline preliminary-injunction dispute | N.D. Cal.; court order and HIT Consultant coverage | 2025-04-25 injunction order | Preliminary injunction granted against certain Strongline Pro activities | Court restricted Strongline Pro sales/marketing to new customers and new-site deployments. |
| Other lawsuits against Commure | Accessible public-web review | — | Not publicly verified in this run | No additional accessible case file was confirmed from public sources reviewed here; absence is not proof of no exposure. |
Counsel should still run a full docket search across state, federal and administrative venues.
verified confidence: high
The same Canopy dispute also shows Commure acting as plaintiff in a strategically important product line.
| case | defendant | court | status | public summary |
|---|---|---|---|---|
| Commure, Inc. v. Canopy Works, Inc. et al. | Canopy Works, Inc. and related parties | Northern District of California | Commure plaintiff; Canopy won preliminary injunction on counterclaims | Shows Commure is not only defendant-adjacent but also an active litigant in a mission-critical product line. |
| Other plaintiff-side cases | Not publicly verified in this run | Accessible public-web review | No additional case confirmed | Additional litigation may exist outside the accessible source set and should be confirmed via counsel or docket search. |
This table only reflects what was accessible without paid dockets or deeper court-database searches.
inconclusive confidence: low
No environmental liability surfaced in the accessible record; the more relevant public safety topic is Commure’s Strongline staff-safety line and the legal continuity issues around it.
partially verified confidence: medium
Commure has visible trademark and licensing signals, but the accessible public record still leaves the full IP schedule unresolved.
| asset | type | jurisdiction or source | public status signal | diligence note |
|---|---|---|---|---|
| COMMURE | Trademark search result | Justia / public trademark search | Search results show Commure, Inc. ownership and serial number 88339310. | Registration classes and live/dead status should be verified directly with USPTO. |
| COMMUREOS | Trademark search result | Justia / public trademark search | Search results show Commure, Inc. ownership and serial number 97497970. | Need prosecution status, classes and international coverage. |
| STRONGLINE | Trademark / brand and related licensed technology | Justia search result and federal court order | Search results show STRONGLINE; court order says the Strongline name was owned by Commure while Canopy retained rights in the licensed technology. | Need full trademark chain, license scope, transition terms and settlement obligations. |
| Canopy licensed technology | Key license / reseller-right exposure | Federal court order | Court says Canopy “will own and retain all intellectual property rights relating to the Licensed Technology.” | Need underlying agreements, amendments, notices and any settlement documents. |
| Public BAA template | Customer-facing legal template | Commure legal page | Public BAA governs PHI use, breach notice and termination handling under underlying agreements. | Need negotiated customer redlines, indemnities and incident history. |
No accessible patent portfolio was independently assembled during this run; counsel should treat that as an open diligence item.
not publicly verifiable confidence: low
Insurance coverage was not publicly disclosed in accessible sources.
partially verified confidence: medium
The accessible public record contains a public BAA and court-described reseller agreement concepts, but not a full contract schedule.
inconclusive confidence: medium
Trust-center, privacy-policy and BAA sources provide compliance signals, but no public enforcement action was found and several claims remain self-reported.
| matter | public signal | date or source | status | diligence note |
|---|---|---|---|---|
| Security controls and hosting posture | AES-256 at rest, TLS 1.2+, US-based infrastructure in SOC2 Type 2-compliant data centers, annual third-party assessments | Trust Center | partially_verified | Need the actual SOC 2 report, pen-test outputs and incident history. |
| HIPAA / California privacy posture | Privacy policy states practices are intended to comply with HIPAA and California law; Daniel Brian named as privacy officer; six-year retention | Privacy policy | verified | Need privacy governance, DSAR metrics, complaint log and any regulator correspondence. |
| Public BAA obligations | 30-day breach-notice outer bound and PHI return/destroy obligations | Current BAA | verified | Need customer-specific security addenda and breach-response evidence. |
| FDA / diagnostics signal | Athelas Home is marketed as an FDA-cleared, CLIA-waived hematology analyzer | Athelas Home page and 2026 financing release | partially_verified | Need direct FDA device-listing / clearance confirmation and post-market obligations. |
| Agency enforcement actions | No public enforcement action located in accessible source set | Public-source review | inconclusive | Absence of evidence is not evidence of absence; counsel should search regulator and enforcement databases directly. |
Public compliance posture is visible, but verification still depends on private audits, certifications and legal review.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Commure as a United States healthcare-and-life-sciences unicorn headquartered in Mountain View with a $6B valuation and select investors General Catalyst and HCA Healthcare. | verified high | SRC-001 |
| EC-002 | Commure announced a $70M financing at a $7B post-money valuation in May 2026, led by General Catalyst with Sequoia Capital, Morgan Stanley and Kirkland & Ellis participating. | verified high | SRC-002 |
| EC-003 | Commure publicly said in June 2025 that it served more than 130 health systems, had ARR in the hundreds of millions that doubled for three consecutive years, and raised $200M from General Catalyst’s CVF. | partially verified medium | SRC-003 |
| EC-004 | The Athelas merger announcement said the combined company was valued at $6B, was at a $100M+ run rate tracking to $125M-$150M by year-end, and would be led by Tanay Tandon as CEO, Deepika Bodapati as COO and Dhruv as CTO. | partially verified medium | SRC-004 |
| EC-005 | Commure publicly disclosed an exclusive ambient-AI partnership with HCA Healthcare after its Augmedix acquisition, while stating that a formal enterprise agreement was still being negotiated. | partially verified medium | SRC-005 |
| EC-006 | Commure publicly positions itself as “The AI-Native Enterprise RCM & Ambient Platform” and lists solution lines across Ambient AI, Dictation, Agents, RCM, Engage, Commure Pro, Strongline and Athelas Home. | verified high | SRC-006 |
| EC-007 | Commure markets Ambient AI as a documentation-plus-coding platform that supports 40 million appointments annually, integrates with 60+ EHRs and offers multiple ambient tiers. | partially verified medium | SRC-007 |
| EC-008 | Commure’s RCM product is publicly described as an end-to-end automation suite covering coding, prior auth, eligibility, submissions, posting and appeals with deep EHR integration. | verified high | SRC-008 |
| EC-009 | Commure Dictation is publicly positioned as a speech-to-cursor clinical-documentation layer built on the same AI that powers tens of millions of ambient encounters. | verified medium | SRC-009 |
| EC-010 | Commure Agents are publicly described as AI-powered colleagues spanning patient calls, scheduling, billing, patient outreach, prior authorization and denials autopilot. | verified high | SRC-010 |
| EC-011 | Commure’s customer page claims 150+ enterprise health systems and highlights named customer stories across documentation, engagement and revenue cycle. | partially verified medium | SRC-011 |
| EC-012 | NEMS publicly reported a 30% documentation-efficiency improvement and materially better multilingual accuracy in an 11-physician Ambient AI pilot. | partially verified medium | SRC-012 |
| EC-013 | A public NYC health-system case study claims Commure lifted average monthly charges from $7.5M to $9.4M, collections from $2.2M to $2.8M, and cut timely-filing denials from 68% to 32%. | partially verified medium | SRC-013 |
| EC-014 | Yale New Haven Health publicly reported that Commure Engage helped drive a 54% relative reduction in no-shows and same-day cancellations in a breast-screening workflow. | partially verified medium | SRC-014SRC-037 |
| EC-015 | Willis Knighton selected Commure after a competitive seven-specialty pilot in which 88% of providers reported benefits and 95% said they would recommend the solution. | partially verified medium | SRC-015 |
| EC-016 | Commure’s partner page says it works with 60+ EHRs, names Epic, MEDITECH, Cerner, athenahealth and NextGen, and describes integrator/GPO partners as channel openers and co-sellers. | partially verified medium | SRC-016 |
| EC-017 | Commure’s Ambient AI is publicly listed in Epic Toolbox, which Commure frames as a distribution and trust signal for Epic-based providers. | partially verified medium | SRC-017 |
| EC-018 | Commure says its Cerner integration eliminates context switching and that Ambient AI is already used at more than 2,000 sites of care and 135 of the largest U.S. health systems, including HCA and Tenet. | partially verified medium | SRC-018 |
| EC-019 | Commure’s people team blog said the company completed four acquisitions and scaled its workforce to over 3,000 employees globally within roughly a year. | partially verified medium | SRC-019 |
| EC-020 | Commure’s recruiting blog said the company hired across nearly every major function and expanded the recruiting team from 2 people to close to 10. | partially verified medium | SRC-020 |
| EC-021 | Commure publicly discloses a Clinical Council and names clinician leaders including Jamie Colbert, Jean-Luc Neptune, Donald Lazure and Aabha Morey. | verified high | SRC-021 |
| EC-022 | Commure’s June 2026 Patient 360 blog says the Pre-Visit Summary feature was released to over a thousand providers across multiple specialties and was built with direct Clinical Council input. | partially verified medium | SRC-022 |
| EC-023 | Commure’s trust center publicly claims AES-256 encryption at rest, TLS 1.2+ in transit, US-based infrastructure in SOC2 Type 2-compliant data centers, annual third-party security assessments, and HIPAA/HITECH alignment. | partially verified medium | SRC-023 |
| EC-024 | Commure’s privacy policy says some data may be PHI, states the policy is intended to comply with HIPAA and California law, names Daniel Brian as privacy officer, retains personal data up to six years after account closure, and explicitly disclaims any guarantee of perfect security. | verified medium | SRC-024 |
| EC-025 | Commure’s public BAA requires breach or security-incident notice without unreasonable delay and in any event within 30 days, and requires PHI return or destruction on termination where feasible. | verified medium | SRC-025 |
| EC-026 | Independent coverage reported that the Northern District of California granted Canopy a preliminary injunction against Commure after finding Commure would likely be found in violation of contractual restrictions related to Strongline Pro. | verified high | SRC-026 |
| EC-027 | The court order shows Commure was the plaintiff against Canopy, describes the Strongline name as owned by Commure, says Canopy retained IP rights in the licensed technology, and enjoins Commure from marketing Strongline Pro to new customers. | verified high | SRC-027 |
| EC-028 | By July 2025, Canopy and Commure publicly announced a partnership under which Canopy would assume management and support of Commure Strongline customers. | verified medium | SRC-028 |
| EC-029 | Public trademark search results show marks tied to Commure, Inc., including COMMURE, COMMUREOS and STRONGLINE, with serial numbers visible from search results. | partially verified medium | SRC-029 |
| EC-030 | Abridge publicly positions itself as an intelligence layer for clinical conversations trusted by 300+ health systems, making it a scaled ambient/documentation competitor. | verified medium | SRC-030 |
| EC-031 | Suki publicly markets itself as ambient clinical intelligence with deep integrations into Epic, Oracle Health, athenahealth and MEDITECH, making it a task-focused ambient competitor with notable EHR depth. | verified medium | SRC-031 |
| EC-032 | AKASA publicly positions itself as a healthcare revenue-cycle GenAI vendor with a client base representing 650+ hospitals and 6,500+ outpatient facilities. | verified medium | SRC-032 |
| EC-033 | R1 publicly describes itself as a Healthcare Revenue OS with system-level automation, 20 years of data and 280 million transactions each year. | verified medium | SRC-033 |
| EC-034 | Across accessible public sources, Commure disclosed headline financing and operating metrics but not audited financial statements, detailed projections, debt schedules, option overhang, customer-cohort retention, or board-level valuation support. | not publicly verifiable medium | SRC-001SRC-002SRC-003SRC-004 |
| EC-035 | Public sources identified customer logos, selected case studies and some integration partners, but did not disclose top-customer revenue concentration, churn, supplier spend, severed-relationship economics, or full supplier agreements. | not publicly verifiable medium | SRC-011SRC-015SRC-016SRC-018 |
| EC-036 | Accessible public materials did not disclose sales compensation, quota size, sales-cycle length, budget sufficiency or the detailed productivity model of the sales force. | not publicly verifiable medium | SRC-016SRC-017SRC-018 |
| EC-037 | Public sources did not disclose executive employment agreements, incentive-stock-plan terms, detailed attrition rates, or other personnel schedules beyond anecdotal scaling signals. | not publicly verifiable medium | SRC-019SRC-020SRC-036 |
| EC-038 | The accessible public record did not disclose Commure’s insurance program, full material-contract schedule, or privately negotiated customer/SaaS terms beyond the public BAA and court-described reseller agreement. | not publicly verifiable medium | SRC-025SRC-027 |
| EC-039 | No public agency enforcement action against Commure surfaced in the accessible sources reviewed for this run, but that absence is not proof that no such actions exist. | inconclusive low | SRC-023SRC-024SRC-025 |
| EC-040 | Commure has public trademark signals and a public IP dispute, but detailed registration status and any patent portfolio could not be fully verified from accessible public records in this run. | inconclusive low | SRC-029SRC-027 |
| EC-041 | Commure’s public materials show dependency on external AI and infrastructure partners including AWS and Anthropic, alongside 60+ EHR integrations. | partially verified medium | SRC-016SRC-034SRC-035 |
| EC-042 | Commure’s careers page showed Mountain View, CA as a public location anchor and zero open positions at crawl time. | inconclusive medium | SRC-036 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.